WO2005094915A1 - 癒着防止用キット、癒着防止用キットの製造方法および癒着防止方法 - Google Patents
癒着防止用キット、癒着防止用キットの製造方法および癒着防止方法 Download PDFInfo
- Publication number
- WO2005094915A1 WO2005094915A1 PCT/JP2005/006369 JP2005006369W WO2005094915A1 WO 2005094915 A1 WO2005094915 A1 WO 2005094915A1 JP 2005006369 W JP2005006369 W JP 2005006369W WO 2005094915 A1 WO2005094915 A1 WO 2005094915A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adhesion
- layer
- film
- adhesion preventing
- tissue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
Definitions
- the present invention relates to an adhesion prevention kit, a method for manufacturing the adhesion prevention kit, and an adhesion prevention method.
- the present invention relates to an adhesion preventing kit for preventing adhesion at the time of guided regeneration treatment of damaged tissue.
- the present invention relates to (A) at least two first films each having a biodegradable substrate layer and an adhesion preventing layer provided on the outermost surface, and at least one second film having an adhesion preventing layer provided on the outermost surface.
- a kit for preventing adhesion is preventing adhesion.
- adhesion frequently occurs between the damaged or defective portion of the organ and a tissue located in the vicinity thereof (hereinafter, also referred to as a peripheral tissue). As a result, it may induce organ dysfunction over time.
- a tissue located in the vicinity thereof hereinafter, also referred to as a peripheral tissue.
- the pericardium is removed and the heart is operated, but depending on the postoperative course, reoperation may be performed. At this time, the pericardium has adhered to the heart and surrounding tissues, and it is necessary to start with the operation of detaching the adhesion. Since the work is performed with great care so as to minimize the bleeding of the patient, it often takes about 3 to 5 hours for this work alone.
- prosthetic membranes covering organs or tissues of the organs have been developed using various materials.
- the prosthetic membrane is made of synthetic fibers, etc.
- excessive calcification, foreign body reaction and inflammation may occur due to lack of biocompatibility.
- Various disadvantages such as reactions occur.
- a bioabsorbable material is used, a material which itself mediates adhesion between a damaged or defective tissue and another tissue corresponding thereto cannot be used.
- the above-mentioned material must be a material having a function of preventing adhesion.
- Materials satisfying the above conditions include, for example, hyaluronic acid and gelatin. Since these materials are mainly extracted and purified from living bodies such as animals, they have good biocompatibility and have already been put to practical use in various medical fields including pharmaceuticals. For example, an anti-adhesion film utilizing hyaluronic acid is mentioned (Patent Documents 1 to 4).
- the membrane made of the above-mentioned biodegradable material has a strength that does not have the strength to be sutured as a prosthetic membrane.
- the present inventors have solved a powerful problem, developed an anti-adhesion membrane having excellent suture strength, and all of the materials constituting the prosthetic membrane were composed of biodegradable and absorbable materials, and filed a patent application. (Patent Documents 5 to 9).
- Patent Document 2 JP 06-073103 A
- Patent Document 3 JP 08-157378 A
- Patent Document 4 JP 08-333333 A
- Patent Document 5 JP 2000-093497 A
- Patent Document 6 JP 2000-210376 A
- Patent Document 7 JP 2000-271271 A
- Patent Document 8 JP 2003-235955 A
- the present invention is a.
- An adhesion prevention kit comprising the following (A) or (B):
- biodegradable substrate layer is composed of a woven fabric, a nonwoven fabric, a sheet, or a sponge.
- adhesion preventing kit according to (1), wherein the adhesion preventing layer contains hyaluronic acid, collagen or gelatin;
- adhesion preventing kit according to (1), wherein the adhesion preventing layer is a sponge of a mixture of collagen and hyaluronic acid.
- a method for producing an adhesion preventing kit comprising: branching a peripheral portion of the biodegradable substrate layer in a direction normal to a membrane surface;
- At least two layers each having a biodegradable substrate layer and an adhesion preventing layer provided on the outermost surface are prepared, and the two films are stacked so that the biodegradable substrate layers face each other and the center is formed.
- an adhesion prevention kit including the following (A) or (B) to prevent adhesion between the damaged or defective tissue and peripheral tissues located around the damaged or defective tissue.
- a method for preventing adhesion characterized by:
- tissue is a pericardium, pleura, diaphragm, brain dura, stomach, esophagus or digestive organ.
- A a biodegradable substrate layer and an adhesion preventing layer each provided on the outermost surface of at least two first films, and a second film having an adhesion preventing layer provided on the outermost surface and having at least one layer strength
- a film comprising a biodegradable substrate layer and an adhesion preventing layer, wherein the outermost surface of the film is an adhesion preventing layer, and the film relates to an adhesion preventing film provided with a tissue sandwiching portion.
- the frequency and extent of adhesions are further reduced as compared with the conventional adhesion prevention film, and thus the time required for the operation of removing adhesions during reoperation is reduced.
- the operator's labor in the operation is reduced, the amount of bleeding of the patient during the operation is greatly suppressed, and the burden on the patient can be reduced.
- FIG. 1 is a conceptual diagram of an operation mode using an adhesion prevention kit according to a first embodiment of the present invention.
- FIG. 2 is a conceptual diagram of an operation mode different from FIG. 1 using the adhesion preventing kit of the first mode of the present invention.
- FIG. 3 is a conceptual diagram of an adhesion preventing kit according to a second embodiment of the present invention.
- FIG. 4 is a conceptual diagram of an operation mode using an adhesion preventing kit according to a second embodiment of the present invention.
- FIG. 5 is a conceptual diagram of an operation using a conventional adhesion preventing film.
- FIG. 6 is a photograph of a pericardial defect in a beagle dog in Example 2.
- FIG. 9 is a photograph taken between the pericardium and the heart three months after the adhesion prevention kit of the present invention was buried in a defective part of the pericardium of a beagle dog.
- FIG. 10 is a photograph of the first membrane sutured to the pericardium of a male beagle dog in Comparative Example 1.
- FIG. 11 is a photograph (80% adhesion) of the pericardium and the heart 3 months after the first membrane was implanted in the pericardial defect of the male beagle dog in Comparative Example 1.
- FIG. 12 is a photograph (50% adhesion) of the pericardium and the heart 3 months after the first membrane was implanted in the pericardial defect of the male beagle dog in Comparative Example 1.
- FIG. 13 is a photograph of a commercially available ePTFE membrane sutured to the pericardium of a male beagle dog in Comparative Example 2.
- FIG. 14 is a photograph taken between the pericardium and the heart three months after a commercially available ePTFE membrane was applied to a pericardial defect in a male beagle dog in Comparative Example 2.
- FIG. 15 is a photograph showing also an oblique force of an adhesion preventing kit according to a second embodiment of the present invention (a tissue holding portion is expanded in a direction parallel to the Y axis in the Z axis direction).
- FIG. 16 is a photograph of the adhesion preventing kit according to the second embodiment of the present invention in FIG. 15, as viewed from the XZ plane.
- FIG. 17 is a photograph in which a portion parallel to the X axis of a tissue holding portion of the adhesion preventing kit in FIG. 16 is expanded in the Z axis direction.
- the adhesion prevention kit of the present invention is used to regenerate a tissue damaged by an accident or the like, or to prosthetic or regenerate an incised or excised tissue during a surgical operation, and to physically reconstruct the damaged or defective tissue. It is used to prevent adhesion with surrounding tissue at a position where it can be contacted.
- the tissue in the present invention refers to an organ in a living body, a membrane tissue covering the organ, and an organ.
- Organs include, for example, heart, liver, stomach, spleen, gall bladder and brain.
- Membrane tissues covering organs include pericardium, pleura, peritoneum, diaphragm, and dura mater.
- the organ includes, for example, a trachea, an esophagus, a stomach organ and the like.
- the damage according to the present invention includes, for example, accidental damage caused by foreign matter from outside the body and surgical damage caused by incision in surgical operation, etc.
- a defect refers to a state in which a part of the thread is missing, and is, for example, a force such as a surgical defect due to resection of an affected part in a surgical operation.
- the peripheral tissue in the present invention refers to a tissue that is located around the damaged or defective tissue and is located at a position where adhesion can occur when the damaged or defective tissue is regenerated.
- the damaged or missing tissue is the pericardium
- the surrounding tissues are the heart, sternum, and lungs.
- an organ such as a trachea, an esophagus, and a stomach organ, it also includes a wall surface facing a damaged or missing part in the organ.
- the adhesion preventing kit of the present invention has the following two forms (A) and (B), and those skilled in the art may select either of them.
- A at least two layers of a first film provided with a biodegradable substrate layer and an adhesion preventing layer on the outermost surface, and at least one second film provided with an adhesion preventing layer on the outermost surface
- B An anti-adhesion film comprising a biodegradable substrate layer and an anti-adhesion layer, wherein the outermost surface of the film is an anti-adhesion layer, and the film is provided with a tissue sandwiching portion.
- the first form (A) of the adhesion preventing kit of the present invention comprises at least two layers of a first film provided with a biodegradable base material layer and an adhesion preventing layer on the outermost surface, respectively.
- the first membrane and the second membrane depend on the damaged or defective tissue undergoing tissue-guided regeneration.For example, in the case of guided regeneration of a pericardium resected in cardiac surgery, the area of the membrane is about l to 200 cm 2, preferably about 15 to 1 50 cm 2, total thickness of about 0. L ⁇ 30mm, and preferably from about 0. 5 to 8 mm, it is limited to this,.
- the first film is at least two layers provided on the outermost surfaces of the biodegradable substrate layer and the adhesion preventing layer, respectively, including at least the biodegradable substrate layer and the adhesion preventing layer.
- the biodegradable substrate layer and the adhesion preventing layer are provided on the outermost surfaces of the biodegradable substrate layer and the adhesion preventing layer.
- the biodegradable base material layer is made of a biodegradable and absorbable polymer that is decomposed and absorbed after a certain period of time when it is buried in a living body, and is damaged or defective.
- Biodegradable and absorbable polymers are materials that can be decomposed and absorbed in a living body after a certain period of time after being implanted in the living body.
- collagen, polylactic acid, polydalicholic acid and the like can be mentioned, and collagen is preferable from the viewpoint of excellent safety after implantation in a living body, and excellent cell adhesion and proliferation.
- collagen that has been treated so as to be soluble in a solvent can be selected.
- enzyme-soluble collagen, acid-soluble collagen, alkali-soluble collagen, and medium-soluble collagen can be selected.
- soluble collagen such as soluble soluble collagen.
- acid-soluble collagen is preferred from the viewpoint of easy handling.
- a rubella collagen which is subjected to a treatment for removing a telopeptide which is an antigenic determinant is preferable, but is not limited thereto.
- collagen The origin of collagen is extracted from the skin, tendons, bones, cartilage, and organs of animal species such as rabbits, pigs, birds, fish, egrets, sheep, rodents, and humans. Perspective Therefore, those derived from pig skin are preferred, but not limited thereto.
- collagen types include type I, type II and type III, and from the viewpoint of easy handling, type I and type III are preferred, but not limited thereto.
- Examples of the form of the biodegradable substrate layer of the present invention include a woven fabric, a nonwoven fabric, a sponge, and a sheet.
- a woven fabric and a nonwoven fabric are preferable from the viewpoint of the suture strength.
- nonwoven fabrics are preferred from the viewpoint of ease of production and cost, but are not limited thereto.
- the outer diameter of the filamentous material is, from the viewpoint of improving the suture strength, a force of about 0.1 to 200 m, preferably about 0.05 to 200 m, and more preferably about 0.1 to 200 m. It is not limited to.
- the above-mentioned thread can be produced according to a conventional method.
- it can be produced by continuously spinning the solution power of the biodegradable and absorbable polymer.
- the concentration of the solution is, from the viewpoint of the strength of the yarn, about 0.1 to 20% by weight, preferably about 1 to 10% by weight.
- Apparatuses used for discharging the solution include, for example, a gear pump, a dispenser, and various types of extruders.A dispenser is preferable from the viewpoint of stable and constant discharge of the solution with little pulsation in order to perform uniform spinning.
- the present invention is not limited to this.
- the solvent for the coagulation bath used in the wet spinning may be any solvent, suspension, emulsion or solution that can coagulate the biodegradable and absorbable polymer.
- an aqueous solution of an inorganic salt, an organic solvent containing an inorganic salt, alcohols, ketones and the like can be mentioned.
- the aqueous solution of an inorganic salt include aqueous solutions of sodium sulfate, sodium chloride, ammonium sulfate, ammonium chloride, magnesium chloride, and the like, particularly aqueous solutions of sodium chloride, sodium sulfate, ammonium sulfate, and the like. Is mentioned.
- Alcohols include, for example, methanol, ethanol, isopropanol, amyl alcohol, pentanol, hexanol, ethylene glycol and the like.
- Ketones include acetone and methyl ethyl ketone. No. Among these, from the viewpoint of the strength of the spun yarn, it is preferable to use ethanol, an ethanol solution of sodium chloride, and an ethanol dispersion solution of sodium salt sodium chloride, but it is not limited thereto.
- the interval between the filaments is about 0.01 to 500 ⁇ m, preferably about 0.1 to 200 / ⁇ , and The intervals are preferably equal, but are not limited thereto.
- the woven fabric can be manufactured, for example, by a method using a weaving machine or the like.
- a weaving machine it is preferable to use the above-mentioned filamentous material as a staple from the viewpoint of preventing the filamentous material from being cut, but the present invention is not limited to this.
- the distance between the filaments is about 0.01 to 500 ⁇ m, preferably about 0.1 to 200 ⁇ m, from the viewpoint of the suture strength.
- m force may be in partial contact.
- the arrangement of the thread-like material includes a first layer in which a plurality of thread-like materials are arranged substantially in parallel and a second layer in which a plurality of thread-like materials are arranged substantially in parallel.
- examples include a form manufactured as a layered body having an acute angle of about 70 ° to 90 °.
- a third layer in which a plurality of filaments are arranged substantially in parallel is arranged in an arrangement direction of the filaments of the second layer and an arrangement of the filaments of the third layer.
- An example is a form in which the acute angle formed by the direction in which the filaments are aligned with the direction is about 70 ° to 90 °.
- the nonwoven fabric of the present invention has a layer (n layers, n is an integer of 2 or more) in which a plurality of thread-like materials are arranged substantially in parallel from the viewpoint of the stitching strength. It is preferable that the upper and lower layers (n-1 layer or n + 1 layer, n is an integer of 2 or more) in contact with the layer have an angular force of about 70 ° to 90 ° at an acute angle with the filamentous material. It is not limited. In addition, the total number of these layered bodies is about 2 to 20 layers, preferably about 4 to 16 layers, from the viewpoint of the suture strength and the weight of the membrane, but is not limited thereto. In the present invention, the nonwoven fabric having the above-mentioned layered form is referred to as a layered nonwoven fabric.
- the above-mentioned sheet refers to a planar film whose one surface is substantially uniformly composed of a biodegradable and absorbable polymer.
- a method of manufacturing by extrusion molding, compression molding, a solvent casting method and the like can be mentioned, and from the viewpoint of manufacturing easiness, the solvent casting method is preferred.
- the present invention is not limited to this.
- the sponge described above is a sponge having a porous structure in which sections having a large number of gaps of uniform or non-uniform size are continuously or discontinuously dispersed by visual judgment and observation under a microscope.
- a solution of a biodegradable polymer is poured into a mold prepared according to the shape of a target tissue damaged portion and formed by a method such as natural drying, vacuum drying, freeze-thawing, or vacuum freeze-drying.
- a freeze-drying method it is preferable to form by a freeze-drying method, but it is not limited to this.
- the vacuum freeze-drying method includes, for example, a method of drying about 0.05 to 30% by weight of a solution at about 0.08 Torr or less from the viewpoint of ease of production. is not.
- a sponge can be obtained by removing the mold force. Further, the above-mentioned sponge is preferably compressed by, for example, a press from the viewpoint of suture strength. The force is not limited to this.
- the biodegradable base material layer is preferably further immersed in a biodegradable and absorbable polymer solution and air-dried, but is not limited thereto.
- Such processing is called binder processing!
- the biodegradable and absorbable polymer in the binder treatment it is preferable to use the same substance as the biodegradable substrate layer from the viewpoint of compatibility and strength with the biodegradable substrate layer, but this is not a limitation. Not something.
- After the biodegradable substrate layer is impregnated with a solution of a biodegradable and absorbable polymer, it is dried by an appropriate drying method such as natural drying, drying under ventilation, drying under reduced pressure, drying under low temperature, or vacuum freeze drying. I do.
- the biodegradable base material layer obtained by the nodering treatment has a significantly higher suture strength than the untreated biodegradable base material layer.
- the concentration of the biodegradable absorbent polymer in the binder treatment is about 0.05 to 30% by weight, and preferably about 0.1 to 10% by weight, from the viewpoint of the handleability of the solution. A force is not limited to this.
- the biodegradable substrate layer of the present invention is most preferably a nonwoven fabric composed of collagen thread, from the viewpoints of ease of production, suture strength, degradation resistance, and safety after implantation in a living body. ,.
- the adhesion preventing layer according to the present invention refers to a layer having an effect of preventing adhesion between a damaged tissue and a peripheral tissue during regeneration of a damaged or defective tissue.
- Raw materials include polymers having an adhesion preventing effect. For example, collagen, gelatin and hyaluronic acid And preferably hyaluronic acid having an excellent adhesion-preventing effect, and particularly preferably a mixture of collagen and hyaluronic acid having improved degradation resistance.
- the hyaluronic acid may be derived from animals or microorganisms.
- alkali metals may be derived from animals or microorganisms.
- the mixing ratio of collagen and hyaluronic acid is about 3: 7 to 7: 3, preferably 5: 5, from the viewpoint of preventing adhesion and degrading resistance, and is not limited to this.
- examples of the shape of the adhesion preventing layer include a sheet and a sponge.
- sponges are preferred from the viewpoint of ease of lamination on the biodegradable substrate layer.
- the method for producing the sheet or sponge may be the same as the method for producing the biodegradable substrate layer described above, but is not limited thereto.
- the sponge composed of a mixture of collagen and hyaluronic acid is most preferred for the anti-adhesion layer of the present invention from the viewpoints of ease of production, anti-adhesion effect, degradation resistance and safety after implantation in a living body. Preferred,.
- the lamination of the biodegradable substrate layer and the adhesion preventing layer in the first film may be performed, for example, by directly forming the adhesion preventing layer on the biodegradable substrate layer, and After forming the adhesion preventing layers, a method of laminating the layers is used. Above all, from the viewpoint of ease of production, a method in which a biodegradable substrate layer and an adhesion preventing layer are separately formed and then laminated is preferable. Force is not limited to this.
- the adhesion preventing layer on the biodegradable base material layer for example, after immersing a biodegradable base material layer made of a nonwoven fabric in a solution of a biodegradable and absorbable polymer
- Examples of the method include a method of forming by a freeze-drying method. The present invention is not limited to this.
- the above-mentioned binder treatment and suturing using a thread are exemplified.
- the above-mentioned binder treatment using a biodegradable and absorbable polymer is not particularly limited.
- the binder treatment may be performed according to the method described above, but is not limited thereto.
- the suture is made of commercially available surgical thread and the biodegradable and absorbable polymer. And a method using a thread-like material. Above all, from the viewpoint of safety at the time of implantation in a living body, it is preferable to sew with a thread-like material made of the above-mentioned biodegradable and absorbable polymer, but it is not limited thereto. From the viewpoint of the strength of the membrane, the interval of the sewing is about 1 to 20 mm, preferably about 2 to: LOmm, and the interval of the sewing machine pitch is about 1 to 20 mm, preferably about 2 to: LOmm. However, the present invention is not limited to this.
- the biodegradable substrate layer and the adhesion preventing layer are preferably further subjected to a crosslinking treatment as necessary.
- a crosslinking treatment By this cross-linking treatment, the decomposition time of the anti-adhesion membrane in the living body can be appropriately controlled.
- the crosslinking method include a chemical crosslinking method, ⁇ -ray irradiation, ultraviolet irradiation, electron beam irradiation, plasma irradiation, and thermal dehydration crosslinking treatment.
- thermal dehydration crosslinking treatment is preferable, but not limited thereto. .
- this cross-linking treatment it is possible to control the in-vivo degradation and absorbability by the cross-linking temperature and the cross-linking time.
- the second film contains at least an adhesion preventing layer.
- the anti-adhesion layer may be manufactured by the same method as the anti-adhesion layer of the first film. Above all, from the viewpoint of production cost, it is preferable that the form is the same as that of the adhesion preventing layer of the first film, but the present invention is not limited to this.
- Preferred examples of the first embodiment (I) of the adhesion preventing kit of the present invention include collagen, from the viewpoints of production cost, ease of production, membrane strength, and safety during implantation in a living body.
- At least two first membranes each having an outermost surface provided with a biodegradable substrate layer which is a nonwoven fabric and an adhesion preventing layer which is a sponge of a mixture of collagen and hyaluronic acid, and collagen and hyaluronic acid on the outermost surface
- This is a form including at least one second film provided with an adhesion preventing layer which is a sponge force of the mixture.
- the second mode ( ⁇ ) of the adhesion preventing kit of the present invention is a film including a biodegradable substrate layer and an adhesion preventing layer, and the outermost surface of the film is an adhesion preventing layer.
- This is an anti-adhesion film in which a tissue sandwiching portion is provided on the membrane, and includes an anti-adhesion film in which a tissue sandwiching portion is provided around the periphery of the film.
- Fig. 3 shows a conceptual diagram, and Figs. 15 to 17 show photographs actually created.
- the area and thickness of the film may be the same as those in the first embodiment ( ⁇ ).
- the biodegradable substrate layer and the adhesion preventing layer in the second embodiment (B) are manufactured by the same method as the biodegradable substrate layer and the adhesion preventing layer in the first embodiment (A). If possible, but not limited to this! /.
- the tissue holding portion in the present invention means a portion that protects the tissue edge by sandwiching the tissue edge.
- the film surface normal direction refers to the arrow direction in FIG. 3 or the Z-axis direction in FIGS.
- the area occupied by the tissue holding portion is set assuming that the area of the film surface of the adhesion preventing film is 100% from the viewpoint of the strength of the film and the ease of holding the tissue. Is about 0.5 to 90%, preferably 5 to 75%, and more preferably about 10 to 50%.
- the tissue holding portion of the present invention includes, for example,
- GO A method of laminating two films composed of a biodegradable substrate layer, bonding or sewing the central portion, and then laminating an adhesion preventing layer on the outer surface of the biodegradable substrate layer.
- a film having an adhesion preventing layer laminated on both sides of the biodegradable base material layer is prepared, and a film is formed between the adhesion preventing layer, the biodegradable base material layer, and the adhesion preventing layer and the biodegradable base material layer. How to make a cut parallel to the surface,
- the two-layered film composed of the biodegradable substrate layer and the adhesion preventing layer has the same structure as the first film in the first embodiment (A) of the present invention.
- the lamination, kneading treatment and suturing of the biodegradable base material layer and the adhesion preventing layer may be performed according to the method described in the first embodiment (A), but are not limited thereto. What! / ,. [0052] Further, the above-mentioned cutting can be achieved by using a general-purpose instrument such as a microtome and a knife.
- Particularly preferred examples of the second embodiment (B) of the adhesion preventing kit of the present invention include collagen from the viewpoints of production cost, ease of production, membrane strength, and safety during implantation in a living body.
- a membrane comprising a biodegradable substrate layer which also has a nonwoven fabric strength and an anti-adhesion layer which is a sponge force of a mixture of collagen and hyaluronic acid, wherein the outermost surface of the membrane is an anti-adhesion layer; This is a mode that includes an adhesion preventing film provided with a tissue holding portion.
- the adhesion prevention kit of the present invention can provide a novel method for preventing adhesion between a damaged or defective tissue and its surrounding tissue.
- adhesion preventing method in each example will be described with reference to the drawings, but the present invention is not limited thereto.
- FIG. 1 shows an example of an adhesion preventing method using the first embodiment (A) of the adhesion preventing kit of the present invention.
- the first biodegradable substrate layer 4 of the first membrane is directed toward the damaged or missing yarn 6 side so as to cover the damaged or missing portion.
- Prosthesis with membrane 1 Next, on the other side of the damaged or missing tissue 6, the second membrane 2 is prosthetic.
- the damaged or defective portion is sandwiched between the first film 1 and the second film 2, and the damaged or defective portion is arranged so as not to be exposed.
- the positions of the first film and the second film may be reversed.
- FIG. 1 The example shown in FIG. 1 is mainly applied to the force that can be applied when tissues such as the pericardium, pleura, cerebral dura, diaphragm, stomach, esophagus or digestive tract are damaged or lost. It is not something.
- FIG. 2 shows another example of the adhesion preventing method using the first embodiment (A) of the adhesion preventing kit of the present invention.
- the second membrane 2 is arranged at a position facing the damaged or defective portion.
- the biodegradable base material layer 41 of the first membrane is directed toward the damaged or missing yarn 6 and the damaged or missing tissue 6 is damaged or damaged.
- the first membrane 1 is used to prosthesis to cover the missing part.
- the damaged or missing part is physically It is possible to provide an adhesion prevention method that is more efficient than in the past, in which there is no direct contact
- the example shown in Fig. 2 is a force that can be mainly applied when a tissue such as the pericardium, pleura, diaphragm, or dura is damaged or defective.
- the present invention is not limited to this.
- FIG. 4 shows an example of an adhesion preventing method using the second embodiment (B) of the adhesion preventing kit of the present invention.
- the damaged or missing tissue 6 is held by the tissue holding portion 8. That is, since the damaged or missing portion is not exposed, it is possible to provide an adhesion prevention method that is more efficient than in the past by physically contacting the surrounding tissues 71, 72 and the like.
- the example shown in FIG. 4 is mainly applied to the force that can be applied when tissues such as the pericardium, pleura, cerebral dura, diaphragm, stomach, esophagus or digestive organ are damaged or defective. It is not something.
- the adhesion prevention method or use using the adhesion prevention kit of the first mode (A) and the second mode (B) of the present invention refers to the method of using a damaged or defective tissue and a surrounding tissue. It is characterized by being separated by an adhesion preventing layer.
- a 1% by weight aqueous solution of hyaluronic acid and an equal amount of a 1% by weight aqueous solution of collagen were mixed to obtain 250 mL of an equal volume mixture of collagen and hyaluronic acid.
- the mixture in an acidic state is neutralized with a 0.1N aqueous sodium hydroxide solution, and then filled into a metal container (approximately 10 cm square) having a rectangular parallelepiped space. Frozen for 12 hours.
- the frozen product was freeze-dried for about 24 hours under reduced pressure (0.1 Ltorr or less) with a freeze dryer (EYELA: FDU-830 type), and then a compressor (Inuchi Seieido: 15 t) (Press machine) at a pressure of 100 kgf / cm 2 .
- a freeze dryer EYELA: FDU-830 type
- a compressor Inuchi Seieido: 15 t
- an adhesion preventing layer about 10 cm square having a sponge force of a mixture of collagen and hyaluronic acid was obtained.
- a 1% by weight aqueous solution of collagen was applied as a binder treatment to the collagen nonwoven fabric to fill gaps between the yarns of the crosslinked collagen layered nonwoven fabric, and then dried. Subsequently, the coating operation and the drying operation were repeated three times, and then a thermal dehydration crosslinking reaction was performed in a vacuum dry oven at 120 ° C for 12 hours. Next, the mixture was neutralized with a 7.5% by weight aqueous sodium hydrogen carbonate solution and air-dried in a clean bench to obtain a biodegradable substrate layer (about 10 cm square) of a tissue regeneration prosthetic membrane composed of a collagen nonwoven fabric.
- the adhesion preventing layer obtained in Example 1 (1) contains a mixture of neutralized collagen and hyaluronic acid on the biodegradable substrate layer composed of the collagen nonwoven fabric obtained in Example 1 (2).
- the solution was applied to adhere the adhesion preventing layer and the biodegradable substrate layer. After air-drying in a clean bench, it was heated in a vacuum dry oven at 110 ° C for 24 hours under reduced pressure (ltorr or less) for 24 hours to perform a thermal dehydration crosslinking reaction, thereby obtaining a first film.
- the anti-adhesion layer produced in Example 1 (1) was used as it was as a second film.
- Example 1 (3) and the second film produced in Example 1 (4) were subjected to ⁇ -ray sterilization under the condition of an irradiation dose of 25 kGy, to thereby obtain the first embodiment of the present invention.
- An adhesion prevention kit was obtained.
- Example 2 Anti-adhesion experiment using the anti-adhesion kit of the present invention
- Example 7 the second membrane prepared in Example 1 (4) was trimmed approximately 5 cm square and inserted through the pericardial defect, and placed at a position facing the pericardial defect created in Example 2 (1). A second membrane was placed on the heart surface ( Figure 7).
- the first membrane prepared in Example 1 (3) was trimmed to about 5 cm square, and immersed in sterile distilled water for injection for about 5 to 10 minutes to be sufficiently softened.
- the collagen nonwoven fabric of the first membrane was fixed by continuous suturing in a state facing the pericardial defect side prepared in Example 2 (1) (FIG. 8). Thereafter, the chest was closed and observation was made for 3 months.
- Comparative Example 1 Anti-adhesion experiment using only the first film of the present invention
- Example 2 The same procedure as in Example 2 was performed except that the step of (2) was not performed. That is, only Example 2 (1) and (3) were performed.
- FIG. 10 shows a photograph in which the first membrane in Comparative Example 1 was fixed to a pericardial defect by continuous suturing.
- the adhesion area ratio refers to a ratio of an adhesion occurrence area when a pericardial defect area is defined as 100%.
- the degree of adhesion was visually determined based on the criteria shown in Table 1.
- the number of confirmed adhesions in Example 2 was 2 out of 6 cases.
- the degree of adhesion was grade 3 in both cases, but the adhesion area ratio was 10% in both cases. In other words, for the adhesion peeling work of the surgeon It required little effort.
- the number of confirmed adhesions in Comparative Example 1 was three, and the degree of adhesion was all grade 3.
- the adhesion area rates were 50, 80 and 100%, respectively. From the above, it has been clarified that the adhesion preventing kit of the present invention has excellent adhesion preventing ability and has a function of regenerating a pericardium in a pericardial defect. Table 2 shows the evaluation results of the adhesion prevention effect.
- FIG. 9 shows a photograph of the adhesion state of Sample No. 1 of Example 2. After the first membrane and the second membrane were decomposed and absorbed, a pericardial-like membrane was regenerated in the pericardial defect, and the pericardium and the heart were strongly attached.
- Figs. 11 and 12 show photographs of the adhesion of Sample Nos. 1 and 4 of Comparative Example 1, respectively.
- the first membrane was degraded and absorbed, and a pericardial-like membrane was regenerated in the pericardial defect, but partial adhesion was observed between the pericardium and the heart.
- Comparative Example 2 An adhesion prevention experiment using a commercially available adhesion prevention film
- FIG. 13 shows a photograph in which the commercially available anti-adhesion membrane of Comparative Example 2 was fixed to the pericardial defect by continuous suturing.
- Example 1 (2) the Noinda treated collagen layered nonwoven collagen 1 weight 0/0 aqueous solution was prepared two, in the central portion 2cm square on, elaborate coating, respectively Re its collagen solution Thereafter, the layered nonwoven fabrics subjected to the binder treatment were bonded to each other. Then, a biodegradable substrate layer was obtained by performing a thermal dehydration bridge at 120 ° C for 12 hours under high vacuum (ltorr or less) in a vacuum dry oven. Then, after neutralizing by immersing in a 7.5% by weight aqueous sodium hydrogen carbonate solution for 30 minutes, washing with distilled water and air-drying in a clean bench, the biodegradable substrate provided with a tissue holding portion is provided.
- a material layer (10 cm square) was obtained.
- a solution containing a mixture of neutralized collagen and hyaluronic acid was applied to both sides of the biodegradable substrate layer, and the solution obtained in Example 1 (1) was applied to both sides of the two biodegradable substrate layers.
- Each of the adhesion preventing layers was laminated. After being air-dried in a clean bench, it is heated in a vacuum dry oven under high vacuum (ltorr or less) at 110 ° C for 24 hours to perform a thermal dehydration crosslinking reaction. ) was prepared.
- Figures 15 to 17 show the photographs.
- the present invention is a breakthrough invention in the field of surgery. Specifically, since the frequency and extent of adhesions are further reduced as compared with conventional anti-adhesion membranes, the time required to remove the adhesions during reoperation is significantly reduced. In other words, the operator's labor in the operation is greatly reduced, and the amount of attendance of the patient at the time of the operation is greatly reduced, and the burden on the patient can be reduced.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05727265.0A EP1731180B1 (en) | 2004-03-31 | 2005-03-31 | Antiadhesive kit, process for producing the same and method of adhesion prevention |
US10/594,801 US20080241203A1 (en) | 2004-03-31 | 2005-03-31 | Antiadhesive Kit, Process for Producing the Same and Method of Adhesion Prevention |
JP2006511824A JP4840136B2 (ja) | 2004-03-31 | 2005-03-31 | 癒着防止用キット、癒着防止用キットの製造方法および癒着防止方法 |
US14/939,374 US20160121031A1 (en) | 2004-03-31 | 2015-11-12 | Antiadhesive Kit and Method of Adhesion Prevention |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004102638 | 2004-03-31 | ||
JP2004-102638 | 2004-03-31 | ||
JP2004264902 | 2004-09-13 | ||
JP2004-264902 | 2004-09-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/594,801 A-371-Of-International US20080241203A1 (en) | 2004-03-31 | 2005-03-31 | Antiadhesive Kit, Process for Producing the Same and Method of Adhesion Prevention |
US14/939,374 Division US20160121031A1 (en) | 2004-03-31 | 2015-11-12 | Antiadhesive Kit and Method of Adhesion Prevention |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005094915A1 true WO2005094915A1 (ja) | 2005-10-13 |
Family
ID=35063550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006369 WO2005094915A1 (ja) | 2004-03-31 | 2005-03-31 | 癒着防止用キット、癒着防止用キットの製造方法および癒着防止方法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20080241203A1 (ja) |
EP (1) | EP1731180B1 (ja) |
JP (1) | JP4840136B2 (ja) |
WO (1) | WO2005094915A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008109979A (ja) * | 2006-10-30 | 2008-05-15 | Kawasumi Lab Inc | 癒着防止材 |
JP2009529374A (ja) * | 2006-03-07 | 2009-08-20 | アクスル インターナショナル | 治療及び癒着防止用生物活性スキャホールド |
JP2010279574A (ja) * | 2009-06-05 | 2010-12-16 | Nipro Corp | 癒着防止膜 |
JP2011500237A (ja) * | 2007-10-30 | 2011-01-06 | バクスター・インターナショナル・インコーポレイテッド | 内臓または体腔壁の欠陥を治療するための再生性の生体機能性コラーゲン生物基質の使用 |
US20110045047A1 (en) * | 2008-10-17 | 2011-02-24 | Confluent Surgical, Inc. | Hemostatic implant |
WO2011081162A1 (ja) * | 2009-12-28 | 2011-07-07 | 川澄化学工業株式会社 | 癒着防止材 |
WO2014141983A1 (ja) | 2013-03-15 | 2014-09-18 | 東レ株式会社 | ポリ乳酸系樹脂を用いた積層フィルム |
JP2015164526A (ja) * | 2014-02-14 | 2015-09-17 | 瀚醫生技股▲分▼有限公司 | 二層複合材料を形成する方法、その方法で形成された二層複合材料、二層複合材料を含む生物医学機器 |
KR20170017869A (ko) | 2014-06-18 | 2017-02-15 | 도레이 카부시키가이샤 | 적층체 및 그 제조 방법 |
WO2017164264A1 (ja) | 2016-03-23 | 2017-09-28 | 東レ株式会社 | 積層体 |
KR20180006371A (ko) | 2015-05-11 | 2018-01-17 | 도레이 카부시키가이샤 | 고분자막 및 그것을 사용한 분산액과 집적체 |
US10456503B2 (en) | 2014-04-24 | 2019-10-29 | Toray University Educational System | Polymer laminate |
US10531988B2 (en) | 2014-12-10 | 2020-01-14 | Toray Industries, Inc. | Laminated film and medical sheet |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011004239A1 (de) * | 2011-02-16 | 2012-08-16 | Gelita Ag | Verwendung eines medizinischen Implantats als Adhäsionsbarriere |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000210376A (ja) | 1999-01-21 | 2000-08-02 | Nissho Corp | 縫合可能な組織再生誘導型癒着防止膜 |
JP2000271207A (ja) | 1999-03-29 | 2000-10-03 | Nissho Corp | 縫合可能な癒着防止膜 |
JP2003235955A (ja) | 2001-12-13 | 2003-08-26 | Nipro Corp | 癒着防止膜 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL74715A0 (en) * | 1984-03-27 | 1985-06-30 | Univ New Jersey Med | Biodegradable matrix and methods for producing same |
US4925924A (en) * | 1984-03-27 | 1990-05-15 | University Of Medicine And Dentistry Of New Jersey | Biocompatible synthetic and collagen compositions having a dual-type porosity for treatment of wounds and pressure ulcers and therapeutic methods thereof |
US4600533A (en) * | 1984-12-24 | 1986-07-15 | Collagen Corporation | Collagen membranes for medical use |
SE8501022L (sv) * | 1985-03-01 | 1986-09-02 | Pharmacia Ab | Format alster och forfarande for dess framstellning |
IT1198449B (it) * | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
US4937270A (en) * | 1987-09-18 | 1990-06-26 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
US5171273A (en) * | 1989-01-13 | 1992-12-15 | University Of Medicine And Dentistry Of New Jersey | Synthetic collagen orthopaedic structures such as grafts, tendons and other structures |
GB2282328B (en) * | 1993-09-29 | 1997-10-08 | Johnson & Johnson Medical | Absorbable structures for ligament and tendon repair |
TW501934B (en) * | 1996-11-20 | 2002-09-11 | Tapic Int Co Ltd | Collagen material and process for making the same |
FR2759084B1 (fr) * | 1997-02-06 | 1999-10-29 | Dev Des Utilisations Du Collag | Materiau collagenique utile notamment pour la prevention d'adherences post-operatoires |
EP1022031B1 (en) * | 1999-01-21 | 2005-03-23 | Nipro Corporation | Suturable adhesion-preventing membrane |
US6773723B1 (en) * | 2000-08-30 | 2004-08-10 | Depuy Acromed, Inc. | Collagen/polysaccharide bilayer matrix |
US20030114061A1 (en) * | 2001-12-13 | 2003-06-19 | Kazuhisa Matsuda | Adhesion preventive membrane, method of producing a collagen single strand, collagen nonwoven fabric and method and apparatus for producing the same |
KR101065155B1 (ko) * | 2002-07-31 | 2011-09-16 | 마스트 바이오서저리 아게 | 이식체와 주위 조직 사이의 유착을 예방하기 위한 기구 및방법 |
-
2005
- 2005-03-31 JP JP2006511824A patent/JP4840136B2/ja not_active Expired - Fee Related
- 2005-03-31 WO PCT/JP2005/006369 patent/WO2005094915A1/ja active Application Filing
- 2005-03-31 US US10/594,801 patent/US20080241203A1/en not_active Abandoned
- 2005-03-31 EP EP05727265.0A patent/EP1731180B1/en not_active Not-in-force
-
2015
- 2015-11-12 US US14/939,374 patent/US20160121031A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000210376A (ja) | 1999-01-21 | 2000-08-02 | Nissho Corp | 縫合可能な組織再生誘導型癒着防止膜 |
JP2000271207A (ja) | 1999-03-29 | 2000-10-03 | Nissho Corp | 縫合可能な癒着防止膜 |
JP2003235955A (ja) | 2001-12-13 | 2003-08-26 | Nipro Corp | 癒着防止膜 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1731180A4 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009529374A (ja) * | 2006-03-07 | 2009-08-20 | アクスル インターナショナル | 治療及び癒着防止用生物活性スキャホールド |
JP2008109979A (ja) * | 2006-10-30 | 2008-05-15 | Kawasumi Lab Inc | 癒着防止材 |
JP2011500237A (ja) * | 2007-10-30 | 2011-01-06 | バクスター・インターナショナル・インコーポレイテッド | 内臓または体腔壁の欠陥を治療するための再生性の生体機能性コラーゲン生物基質の使用 |
US8790698B2 (en) | 2007-10-30 | 2014-07-29 | Baxter International Inc. | Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects |
US9889230B2 (en) * | 2008-10-17 | 2018-02-13 | Covidien Lp | Hemostatic implant |
US20110045047A1 (en) * | 2008-10-17 | 2011-02-24 | Confluent Surgical, Inc. | Hemostatic implant |
JP2010279574A (ja) * | 2009-06-05 | 2010-12-16 | Nipro Corp | 癒着防止膜 |
WO2011081162A1 (ja) * | 2009-12-28 | 2011-07-07 | 川澄化学工業株式会社 | 癒着防止材 |
US8821900B2 (en) | 2009-12-28 | 2014-09-02 | Kawasumi Laboratories, Inc. | Anti-adhesion material |
JP5686297B2 (ja) * | 2009-12-28 | 2015-03-18 | 川澄化学工業株式会社 | 癒着防止材 |
WO2014141983A1 (ja) | 2013-03-15 | 2014-09-18 | 東レ株式会社 | ポリ乳酸系樹脂を用いた積層フィルム |
JP2015164526A (ja) * | 2014-02-14 | 2015-09-17 | 瀚醫生技股▲分▼有限公司 | 二層複合材料を形成する方法、その方法で形成された二層複合材料、二層複合材料を含む生物医学機器 |
US10456503B2 (en) | 2014-04-24 | 2019-10-29 | Toray University Educational System | Polymer laminate |
KR20170017869A (ko) | 2014-06-18 | 2017-02-15 | 도레이 카부시키가이샤 | 적층체 및 그 제조 방법 |
US10786980B2 (en) | 2014-06-18 | 2020-09-29 | Toray Industries, Inc. | Laminate and production method therefor |
US10531988B2 (en) | 2014-12-10 | 2020-01-14 | Toray Industries, Inc. | Laminated film and medical sheet |
KR20180006371A (ko) | 2015-05-11 | 2018-01-17 | 도레이 카부시키가이샤 | 고분자막 및 그것을 사용한 분산액과 집적체 |
US10563025B2 (en) | 2015-05-11 | 2020-02-18 | Toray Industries, Inc. | Polymer film, and dispersion liquid and agglomerate using same |
WO2017164264A1 (ja) | 2016-03-23 | 2017-09-28 | 東レ株式会社 | 積層体 |
KR20180111893A (ko) | 2016-03-23 | 2018-10-11 | 도레이 카부시키가이샤 | 적층체 |
US11046061B2 (en) | 2016-03-23 | 2021-06-29 | Toray Industries, Inc. | Laminate |
Also Published As
Publication number | Publication date |
---|---|
US20080241203A1 (en) | 2008-10-02 |
EP1731180A1 (en) | 2006-12-13 |
JP4840136B2 (ja) | 2011-12-21 |
JPWO2005094915A1 (ja) | 2008-02-14 |
US20160121031A1 (en) | 2016-05-05 |
EP1731180B1 (en) | 2017-10-11 |
EP1731180A4 (en) | 2010-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005094915A1 (ja) | 癒着防止用キット、癒着防止用キットの製造方法および癒着防止方法 | |
TWI461227B (zh) | 再生生物功能性膠原生物基質用來治療內臟或體壁缺陷的用途 | |
EP1022031B1 (en) | Suturable adhesion-preventing membrane | |
JP3542170B2 (ja) | 医用材料及びその製造方法 | |
US8932619B2 (en) | Dural repair material | |
EP1319415B1 (en) | Adhesion preventive membrane, method of producing a collagen single strand, collagen nonwoven fabric and method and apparatus for producing the same | |
WO1999064655A1 (fr) | Materiau collagenique et procede de production | |
JP2000271207A (ja) | 縫合可能な癒着防止膜 | |
JP4968976B2 (ja) | コラーゲン材及びその製法 | |
JP3726280B2 (ja) | 医療用コラーゲン膜 | |
JP2000210376A (ja) | 縫合可能な組織再生誘導型癒着防止膜 | |
JP4345296B2 (ja) | 癒着防止膜 | |
JP4595279B2 (ja) | 癒着防止膜 | |
JP2010029684A (ja) | コラーゲン材及びその製法 | |
JP5017936B2 (ja) | 切除領域に固定手段を備えた組織再生器具の前駆体 | |
JP5563182B2 (ja) | 解除可能な固定手段を備えた組織再生器具の前駆体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511824 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10594801 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2005727265 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005727265 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727265 Country of ref document: EP |